Invokana Lawsuit Attorneys at Bernstein Liebhard LLP Note New Class Action Filing in Canada

October 1, 2015 - A new Invokana lawsuit (http://www.invokanalawsuitcenter.com/) has been filed in the Ontario Superior Court of Justice by a Canadian woman who allegedly suffered kidney damage related to the use of the Type 2 diabetes medication. According to the Statement of Claim, the lawsuit seeks class action status on behalf of all Canadians who were allegedly harmed by Invokana, and accuses the manufacturers of the drug of failing to warn doctors of its potential side effects. (Court File No. W-15-536111)

"This lawsuit was filed just months after regulators in the U.S., Canada and Europe announced safety reviews of Invokana and other SGLT2 inhibitors because of a possible association with diabetic ketoacidosis. Our Firm is currently investigating a number of Invokana claims, and we will be monitoring this matter closely," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is investigating potential Invokana lawsuits on behalf of Type 2 diabetes patients who were diagnosed with ketoacidosis, allegedly due to their use of this or another SGLT2 inhibitor.

FDA Safety Review
Approved in 2013, Invokana was the first SGLT 2 inhibitor to come to market in the U.S. A number of other Type 2 diabetes drugs in this class have since been approved by the U.S. Food & Drug Administration (FDA), including Invokamet, Farxiga, Jardiance, Xigduo XR and Glyxambi. In May 2015, the FDA announced that it was investigating a possible link between the use of these medications and diabetic ketoacidosis, a dangerous condition that can lead to diabetic coma and death. According to the agency, its adverse event database had logged 20 reports of the condition among SGLT2 inhibitor patients between May 2013 and June 6, 2014. In all cases, patients required emergency room treatment or hospitalization.

In the weeks that followed, Health Canada and the European Medicines Agency (EMA) announced similar safety reviews. Health Canada noted that its database had received one report of ketoacidosis in an SGLT2 inhibitor patient, while the EMA revealed that the EudraVigilance database had received 101 such reports as of May 19, 2015.

Bernstein Liebhard LLP is currently evaluating potential Invokana lawsuits on behalf of Type 2 diabetics who were hospitalized with ketoacidosis while using this drug or any other SGLT2 inhibitor. To learn more, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.invokanalawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author